Biocompatible, biostable coating of medical surfaces

• US 20050129731A1
• Filed: 11/03/2004
• Published: 06/16/2005
• Est. Priority Date: 11/03/2003
• Status: Abandoned Application

• Current Assignee: Hemoteq AG (Freudenberg & Company KG)
• Original Assignee: Hemoteq AG (Freudenberg & Company KG)
• Inventors: Hoffmann, Michael, Horres, Roland, Faust, Volker, Hoffmann, Erika, Di Biase, Donato
• Application Number:
  US10/979,977
• Publication Number:
  US 20050129731A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61K 31/365 Lactones
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 31/737 Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate A61K31/727 takes precedence
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61L 31/10 Macromolecular materials

Abstract

The invention relates to medical products with at least one biocompatible biostable polysulfone coating with which the elution kinetics of the incorporated and/or deposited at least one antiproliferative, antiinflammatory, antiphlogistic and/or antithrombotic active agent can be controlled via the admixing of at least one hydrophilic polymer in a suitable amount and as well as an local separation of different active agents and active agent combinations respectively can be achieved by means of the layer system of biostable polymers, methods of manufacturing these medical products as well as their use especially in the form of stents for prevention of restenosis.

Claims

1. Medical product, characterized in that its surface is covered at least in part with at least one biostable polysulfone layer.

2. Medical product according to claim 1, characterized in that the polysulfone is selected from the group comprising:

polyethersulfone, substituted polyethersulfone, polyphenylsulfone, substituted polyphenylsulfone, polysulfone block copolymers, perfluorinated polysulfone block copolymers, semifluorinated polysulfone block copolymers, substituted polysulfone block copolymers and/or mixtures of the aforementioned polymers.

3. Medical product according to claim 1, characterized in that the at least one biostable polysulfone layer comprises at least one hydrophilic polymer.

4. Medical product according to claim 3, characterized in that the polysulfone with the at least one hydrophilic polymer is present in a mixture ratio of 50% by weight:

50% by weight up to 99.999% by weight;

0.001% by weight.

5. Medical product according to claim 3, characterized in that the hydrophilic polymer is selected from the group comprising:

polyvinylpyrrolidone, glycerine, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyhydroxyethyl methacrylates, polyacrylamide, polyvalerolactones, poly-ε

-decalactones, polylactone acid, polyglycolic acid, polylactides, polyglycolides, copolymers of polylactides and polyglycolides, poly-ε

-caprolactone, polyhydroxybutanoic acid, polyhydroxybutyrates, polyhydroxyvalerates, polyhydroxybutyrate-co-valerates, poly(1,4-dioxane-2,3-diones), poly(1,3-dioxane-2-ones), poly-p-dioxanones, polyanhydrides such as polymaleic anhydrides, fibrin, polycyanoacrylates, polycaprolactoned imethylacrylates, poly-b-maleic acid, polycaprolactone butylacrylates, multiblock polymers from oligocaprolactone dioles and oligodioxanone dioles, polyether ester multiblock polymers from PEG and polybutylene terephthalate, polypivotolactones, polyglycolic acid trimethyl-carbonates, polycaprolactone-glycolides, poly-g-ethylglutamate, poly(DTH-iminocarbonate), poly(DTE-co-DT-carbonate), poly(bisphenol-A-iminocarbonate), polyorthoesters, polyglycolic acid trimethyl-carbonates, polytrimethylcarbonates, polyiminocarbonates, poly(N-vinyl)-pyrrolidone, polyvinylalcohols, polyesteramides, glycolated polyesters, polyphosphoesters, polyphosphazenes, poly[p-carboxyphenoxy)propane], polyhydroxypentanoic acid, polyanhyd rides, polyethyleneoxide-propyleneoxide, soft polyurethanes, polyurethanes with amino acid residues in the backbone, polyether esters, polyethyleneoxide, polyalkeneoxalates, polyorthoesters as well as copolymers thereof, lipids, carrageenans, fibrinogen, starch, collagen, protein based polymers, polyamino acids, synthetic polyamino acids, zein, modified zein, polyhydroxyalkanoates, pectic acid, actinic acid, modified and non modified fibrin and casein, carboxymethyl sulphate, albumin, hyaluronic acid, chitosan and its derivatives, chondroitine sulphate, dextran, b-cyclodextrins, copolymers with PEG and polypropylene glycol, gum arabicum, guar, gelatine, collagen, collagen-N-hydroxysuccinimide, lipids, phospholipids, modifications and copolymers and/or mixtures of the afore mentioned substances.

6. Medical product according to claim 5, characterized in that the hydrophilic polymer is selected from the group comprising:

polyvinylpyrrolidone polyethylene glycol, polypropylene glycol and/or glycerine.

7. Medical product according to claim 1, characterized in that a pore size of the polysulfone coating is determined by the mixing ratio of polysulfone with the at least one hydrophilic polymer.

8. Medical product according to claim 1, characterized in that at least one antiproliferative, antiinflammatory, antiphlogistic and/or antithrombotic active agent is present in, under and/or on the at least one biostable polysulfone layer with or without the at least one hydrophilic polymer.

9. Medical product according to claim 1, characterized in that the biostable layer is bound adhesively or covalently on the surface of the medical product.

10. Medical product according to claim 1, characterized in that the coating of the surface of the medical product consists of one, two, three or more layers.

11. Medical product according to claim 1, characterized in that at least one layer of completely desulphated and N-reacetylated heparin, desulphated and N-reacetylated heparin, N-carboxymethylated and/or partially N-acetylated chitosan and/or mixtures of these substances is present under and/or on the at least one biostable polysulfone layer with or without the at least one hydrophilic polymer.

12. Medical product according to claim 1, characterized in that the at least one antiproliferative, antiinflammatory, antiphlogistic and/or antithrombotic active agent is selected from the group comprising:

sirolimus (rapamycin), everolimus, somatostatin, tacrolimus, roxithromycin, dunaimycin, ascomycin, bafilomycin, erythromycin, midecamycin, josamycin, concanamycin, clarithromycin, troleandomycin, folimycin, cerivastatin, simvastatin, lovastatin, fluvastatin, rosuvastatin, atorvastatin, pravastatin, pitavastatin, vinblastine, vincristine, vindesine, vinorelbine, etoposide, teniposide, nimustine, carmustine, lomustine, cyclophosphamide, C-type natriuretic peptide (CNP), 4-hydroxycyclophosphamide, estramustine, melphalan, ifosfamide, trofosfamide, chlorambucil, bendamustine, dacarbazine, busulfan, procarbazine, treosulfan, temozolomide, thiotepa, daunorubicin, doxorubicin, aclarubicin, epirubicin, mitoxantrone, idarubicin, bleomycin, mitomycin, dactinomycin, methotrexate, fludarabine, fludarabine-5′

-dihydrogenphosphate, cladribine, mercaptopurine, thioguanine, cytarabine, fluorouracil, gemcitabine, capecitabine, docetaxel, carboplatin, cisplatin, oxaliplatin, amsacrine, irinotecan, topotecan, hydroxycarbamide, miltefosine, pentostatin, aldesleukin, tretinoin, asparaginase, pegaspargase, anastrozole, exemestane, letrozole, formestane, aminoglutethimide, adriamycin, azithromycin, spiramycin, cepharantin, smc proliferation inhibitor-2w, epothilone A and B, mitoxantrone, azathioprine, mycophenolatmofetil, c-myc-antisense, b-myc-antisense, betulinic acid, camptothecin, lapachol, 1-lapachone, podophyllotoxin, betulin, podophyllic acid 2-ethylhydrazide, molgramostim (rhuGM-CSF), peginterferon α

-2b, lenograstim (r-HuG-CSF), filgrastim, macrogol, dacarbazine, basiliximab, daclizumab, selectin (cytokine antagonist), CETP inhibitor, cadherines, cytokinin inhibitors, COX-2 inhibitor, NFkB, angiopeptin, ciprofloxacin, camptothecin, fluroblastin, monoclonal antibodies, which inhibit the muscle cell proliferation, bFGF antagonists, probucol, prostaglandins, 1,11-dimethoxycanthin-6-one, 1-hydroxy-11-methoxycanthin-6-one, scopoletin, colchicine, NO donors such as pentaerythritol tetranitrate and syndnoeimines, S-nitrosoderivatives, tamoxifen, staurosporine, β

-estradiol, α

-estradiol, estrone, estriol, ethinylestradiol, fosfestrol, medroxyprogesterone, estradiol cypionates, estradiol benzoates, tranilast, kamebakaurin and other terpenoids, which are applied in the therapy of cancer, verapamil, tyrosine kinase inhibitors (tyrphostines), cyclosporine A, paclitaxel and derivatives thereof such as 6-α

-hydroxy-paclitaxel, baccatin, taxotere and other, synthetically produced as well as from native sources obtained macrocyclic oligomers of carbon suboxide (MCS) and derivatives thereof, mofebutazone, acemetacin, diclofenac, lonazolac, dapsone, o-carbamoylphenoxyacetic acid, lidocaine, ketoprofen, mefenamic acid, piroxicam, meloxicam, chloroquine phosphate, penicillamine, hydroxychloroquine, auranofin, sodium aurothiomalate, oxaceprol, celecoxib, β

-sitosterin, ademetionine, myrtecaine, polidocanol, nonivamide, levomenthol, benzocaine, aescin, ellipticine, D-24851 (Calbiochem), colcemid, cytochalasin A-E, indanocine, nocodazole, S 100 protein, bacitracin, vitronectin receptor antagonists, azelastine, guanidyl cyclase stimulator, tissue inhibitor of metal proteinase-1 and -2, free nucleic acids, nucleic acids incorporated into virus transmitters, DNA and RNA fragments, plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, antisense oligonucleotides, VEGF inhibitors, IGF-1, active agents from the group of antibiotics such as cefadroxil, cefazolin, cefaclor, cefotaxim, tobramycin, gentamycin, penicillins such as dicloxacillin, oxacillin, sulfonamides, metronidazol, antithrombotics such as argatroban, aspirin, abciximab, synthetic antithrombin, bivalirudin, coumadin, enoxaparin, desulphated and N-reacetylated heparin (hemoparin®

), tissue plasminogen activator, GpIIb/IIIa platelet membrane receptor, factor X_a inhibitor antibody, heparin, hirudin, r-hirudin, PPACK, protamin, prourokinase, streptokinase, warfarin, urokinase, vasodilators such as dipyramidole, triazolopyrimidine (trapidil®

), nitroprussides, PDGF antagonists such as triazolopyrimidine and seramin, ACE inhibitors such as captopril, cilazapril, lisinopril, enalapril, losartan, thiolprotease inhibitors, prostacyclin, vapiprost, interferon α

, β and

γ

, histamine antagonists, serotonin blockers, apoptosis inhibitors, apoptosis regulators such as p65 NF-kB or Bcl-xL antisense oligonucleotides, halofuginone, nifedipine, tocopherol, tranilast, molsidomine, tea polyphenols, epicatechin gallate, epigallocatechin gallate, Boswellic acids and derivatives thereof, leflunomide, anakinra, etanercept, sulfasalazine, etoposide, dicloxacillin, tetracycline, triamcinolone, mutamycin, procainamid, retinoic acid, quinidine, disopyramide, flecainide, propafenone, sotalol, amidorone, natural and synthetically produced steroids such as bryophyllin A, inotodiol, maquiroside A, ghalakinoside, mansonine, strebloside, hydrocortisone, betamethasone, dexamethasone, non-steroidal substances (NSAIDS) such as fenoprofen, ibuprofen, indomethacin, naproxen, phenylbutazone and other antiviral agents such as acyclovir, ganciclovir and zidovudine, antimycotics such as clotrimazole, flucytosine, griseofulvin, ketoconazole, miconazole, nystatin, terbinafine, antiprozoal agents such as chloroquine, mefloquine, quinine, moreover natural terpenoids such as hippocaesculin, barringtogenol-C21-angelate, 14-dehydroagrostistachin, agroskerin, agrostistachin, 17-hydroxyagrostistachin, ovatodiolids, 4,7-oxycycloanisomelic acid, baccharinoids B1, B2, B3 and B7, tubeimoside, bruceanol A, B and C, bruceantinoside C, yadanziosides N and P, isodeoxyelephantopin, tomenphantopin A and B, coronarin A, B, C and D, ursolic acid, hyptatic acid A, zeorin, iso-iridogermanal, maytenfoliol, effusantin A, excisanin A and B, longikaurin B, sculponeatin C, kamebaunin, leukamenin A and B, 13,18-dehydro-6-α

-senecioyloxychaparrin, taxamairin A and B, regenilol, triptolide, moreover cymarin, apocymarin, aristolochic acid, anopterin, hydroxyanopterin, anemonin, protoanemonin, berberine, cheliburin chloride, cictoxin, sinococuline, bombrestatin A and B, cudraisoflavone A, curcumin, dihydronitidine, nitidine chloride, 12-β

-hydroxypregnadiene-4,16-diene-3,20-dione, bilobol, ginkgol, ginkgolic acid, helenalin, indicine, indicine-N-oxide, lasiocarpine, inotodiol, glycoside 1a, podophyllotoxin, justicidin A and B, larreatin, malloterin, mallotochromanol, isobutyrylmallotochromanol, maquiroside A, marchantin A, maytansine, lycoridicin, margetine, pancratistatin, liriodenine, bisparthenolidine, oxoushinsunine, aristolactam-AII, periplocoside A, bisparthenolidine, periplocoside A, ghalakinoside, ursolic acid, deoxypsorospermin, psychorubin, ricin A, sanguinarine, manwu wheat acid, methylsorbifolin, sphatheliachromen, stizophyllin, mansonine, strebloside, akagerine, dihydrousambarensine, hydroxyusambarine, strychnopentamine, strychnophylline, usambarine, usambarensine, berberine, liriodenine, oxoushinsunine, daphnoretin, lariciresinol, methoxylariciresinol, syringaresinol, umbelliferon, afromoson, acetylvismione B, desacetylvismione A, vismione A and B.

13. Medical product according to claim 11, characterized in that the at least one antiproliferative, antiinflammatoric, antiphlogistic and/or antithrombotic active agent is selected from the group comprising:

paclitaxel and its derivatives, β

-estradiol, simvastatin, PI-88 (sulphated oligosaccharide;

Progen Ind.), macrocyclic carbon suboxides (MCS) and their derivatives, trapidil®

, N-(pyridine-4-yl)-[1-4-(4-chlorobenzyl)-indol-3-yl]-glyoxylamide (D-24851), activated protein C (aPC), Ac-YVAD-CMK, Anginex (β

-Pep25), Neovastat®

, cryptophycin 52, and tacrolimus.

14. Medical product according to claim 1, characterized in that the at least one antiproliferative, antiinflammatoric, antiphlogistic and/or antithrombotic active agent is contained in a pharmaceutically active concentration of 0.001 to 20 mg per cm² of surface.

15. Medical product according to claim 1, characterized in that in the case of multiple layer systems the last layer is a pure active agent layer covalently and/or adhesively bound.

21. Medical products according to claim 1, characterized in that the at least one antiproliferative, antiinflammatory, antiphlogistic and/or antithrombotic active agent is released in a controlled manner through the surface coating.

22. Medical products according to claim 21, characterized in that the respective antiproliferative, antiinflammatory, antiphlogistic and/or antithrombotic active agent is contained in a pharmaceutically active concentration of 0.001-10 mg per cm² of medical product surface and per layer bearing the active agent.

23. Medical products according to claim 1, characterized in that in respect of the medical product a stent is concerned.

16. Method of biocompatible coating of medical products, characterized in the steps:

a. Providing a stent, and

b. depositing at least one biostable polysulfone layer with or without at least one hydrophilic polymer, and

c. depositing and/or incorporating at least one antiproliferative, antiinflammatory, antiphlogistic and/or antithrombotic active agent on and/or in the biostable layer, or

b′

. depositing at least one biostable polysulfone layer with or without the at least one hydrophilic polymer together with at least one antiproliferative, antiinflammatory, antiphlogistic and/or antithrombotic active agent.

17. Method according to claim 16, comprising the step b′

and the further step;

c′

. Depositing of at least one antiproliferative, antiinflammatory, antiphlogistic and/or antithrombotic active agent on the biostable polymer layer.

18. Method according to claim 16, comprising the further step:

d. Depositing of at least a second biostable polysulfone layer.

19. Method according to claim 16, characterized in that on and/or under the at least one biostable polysulfone layer at least one layer of completely desulphated and N-reacetylated heparin, desulphated and N-reacetylated heparin, N-carboxymethylated and/or partially N-acetylated chitosan and/or of mixtures of these substances is deposited.

20. Medical products obtainable accordingly to one method according to claim 16.